StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Primaxin (imipenem and cilastatin, legacy) by Quarter

Primaxin (imipenem and cilastatin, legacy) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)

QuarterlyAnnual

Merck Primaxin (imipenem and cilastatin, legacy): -28.0% in Q4 2023. No newer figure appears in the documents we track.

Latest, Q4 2023
-28.0%
Period ended Dec 31, 2023
Change on a year earlier
–
History
24 quarters
Since Q4 2017
Sources
24
Documents cited below

Where the Q4 2023 figure comes from

“|| Primaxin | 80 | 53 | 41 | 39 | 213 | 58 | 64 | 63 | 54 | 239 | -28 | -28 | -11 | -6”

Source: Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗

Reported in Form 8-K Table 3 / 10-K / 10-Q MD&A.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPrimaxin (imipenem and cilastatin, legacy) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)Year on yearSource
Q4 2023Dec 31, 2023-28.0%–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2023Sep 30, 2023-31.0%-26.0 ptsForm 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗
Q2 2023Jun 30, 2023-12.0%-20.0 ptsForm 8-K (tm2322190d1_ex99-1.htm, filed 2023-08-01) ↗
Q1 2023Mar 31, 202348.0%+59.0 ptsForm 8-K (tm2313695d1_ex99-1.htm, filed 2023-04-27) ↗
Q3 2022Sep 30, 2022-5.0%+7.0 ptsForm 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2022Jun 30, 20228.0%+22.0 ptsForm 8-K (tm2221828d1_ex99-1.htm, filed 2022-07-28) ↗
Q1 2022Mar 31, 2022-11.0%-28.0 ptsForm 8-K (tm2213615d1_ex99-1.htm, filed 2022-04-28) ↗
Q4 2021Dec 31, 20212.0%+14.0 ptsForm 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q3 2021Sep 30, 2021-12.0%-8.0 ptsForm 8-K (tm2131077d1_ex99-1.htm, filed 2021-10-28) ↗
Q2 2021Jun 30, 2021-14.0%-8.0 ptsForm 8-K (tm2123400d1_ex99-1.htm, filed 2021-07-29) ↗
Q1 2021Mar 31, 202117.0%+28.0 ptsForm 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q4 2020Dec 31, 2020-12.0%-39.0 ptsForm 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Q3 2020Sep 30, 2020-4.0%-14.0 ptsForm 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2020Jun 30, 2020-6.0%-18.0 ptsForm 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2020Mar 31, 2020-11.0%+3.0 ptsForm 8-K (tm2016917d1_ex99-1.htm, filed 2020-04-28) ↗
Q4 2019Dec 31, 201927.0%+52.0 ptsForm 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗

Cite this data

StockData. (2026). Merck Primaxin (imipenem and cilastatin, legacy) (%), quarterly Q4 2017–Q4 2023 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-primaxin-ww-exfx-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.